- All
- Media Releases
- ad hoc Releases
26.07.2024
Substantial pipeline progress at several portfolio companies offsets rate-related market volatility
26.07.2024
BB Biotech AG publishes its interim report and announces a new head of its investment management team
26.04.2024
BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
26.04.2024
BB Biotech AG publishes its interim report
21.03.2024
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
16.02.2024
BB Biotech AG publishes its 2023 annual report
19.01.2024
End of year biotech equity market rally – M&A and end of rate hike cycle
19.01.2024
BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
20.10.2023
Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
20.10.2023
BB Biotech AG publishes its interim report
21.08.2023
Delisting from Borsa Italiana
21.07.2023
Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
21.07.2023
BB Biotech AG publishes its interim report
21.04.2023
Lackluster first quarter for biotech stocks
21.04.2023
BB Biotech AG publishes its interim report
23.03.2023
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
17.02.2023
BB Biotech AG publishes its 2022 annual report
20.01.2023
Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
20.01.2023
BB Biotech AG closes the 2022 fiscal year with a loss
21.10.2022
US drug pricing legislation drives biotech business to adapt for further innovation
21.10.2022
BB Biotech AG publishes its interim report
22.09.2022
22.09.2022 Rivus Pharmaceuticals Closes $132 Million Series B with participation of BB Biotech
22.07.2022
First signs of increased M&A activity due to attractive valuations
22.07.2022
BB Biotech AG publishes its interim report
22.04.2022
Increased investment level balanced by established core holdings
22.04.2022
BB Biotech AG publishes its interim report
12.04.2022
BB Biotech AG concludes its share buyback program and launches a new buyback program
17.03.2022
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
18.02.2022
BB Biotech AG publishes its 2021 annual report
21.01.2022
2021 was a difficult year for biotech equity markets – increased dividend of CHF 3.85 proposed
21.01.2022
BB Biotech AG closes the 2021 fiscal year with a loss
22.10.2021
BB Biotech increases positions in oncology and CNS
22.10.2021
BB Biotech AG publishes interim report
23.07.2021
Solid second quarter for the biotech industry
23.07.2021
BB Biotech AG publishes interim report
23.04.2021
Sector re-valuation used for portfolio investments
23.04.2021
BB Biotech AG publishes interim report
18.03.2021
Shareholders at BB Biotech AG’s AGM approve all proposals
19.02.2021
BB Biotech AG publishes its 2020 annual report
22.01.2021
Vaccines leading the way out of the pandemic
22.01.2021
BB Biotech AG closes the 2020 fiscal year with a profit
23.10.2020
BB Biotech AG publishes interim report
23.10.2020
Biotech M&A picks up
24.07.2020
Innovative biotech companies lead efforts
24.07.2020
BB Biotech AG publishes its interim report
24.04.2020
Resilient biotech sector despite widespread market turmoil
24.04.2020
BB Biotech AG publishes its interim report
02.04.2020
«Coronavirus ist primär kein Investment Case» (in German)
19.03.2020
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals
21.02.2020
BB Biotech AG publishes its 2019 annual report
17.01.2020
BB Biotech benefits from M&A transactions
17.01.2020
BB Biotech AG closes the 2019 fiscal year with a profit
20.11.2019
Expansion of the Board of Directors
18.10.2019
Political factors weigh on biotech equity markets
18.10.2019
BB Biotech AG publishes its interim report
19.07.2019
BB Biotech AG publishes its interim report
19.07.2019
Consolidation leaves a mark on results
26.04.2019
Strong 1st quarter for BB Biotech
26.04.2019
BB Biotech AG reports results
11.04.2019
Completion of the current share buyback program
21.03.2019
Results Annual General Meeting
15.02.2019
BB Biotech AG publishes its 2018 annual report
23.01.2019
Starker Jahresauftakt für die Biotechbranche (in German)
18.01.2019
BB Biotech invests gains of M&A transactions in new technologies
18.01.2019
BB Biotech AG closes the 2018 fiscal year with a loss